Patents by Inventor Takahiko Taniguchi

Takahiko Taniguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Silencer for automobile and manufacturing method thereof
    Patent number: 10525905
    Abstract: The present invention discloses a silencer for automobile. The silencer is formed by press molding. The silencer has a first molded surface and a second molded surface which are opposite to each other in a thickness direction. The silencer at least includes a first fiber layer on which the first molded surface is formed and a second fiber layer integrated with an opposite surface to the first molded surface, the opposite surface being on the first fiber layer. Fibers of the second fiber layer exist partly on the opposite surface on the first fiber layer.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 7, 2020
    Assignee: HAYASHI TELEMPU CORPORATION
    Inventors: Shuzo Iwata, Arata Tajima, Takahiko Taniguchi, Junpei Shimomura, Kazuya Kusama
  • Nitrogenated heterocyclic compound
    Patent number: 10017508
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: July 10, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki
  • Heterocyclic compound
    Patent number: 9944596
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 17, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro Banno, Masahiro Kamaura, Takahiko Taniguchi, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
  • SILENCER FOR AUTOMOBILE AND MANUFACTURING METHOD THEREOF
    Publication number: 20170369005
    Abstract: The present invention discloses a silencer for automobile. The silencer is formed by press molding. The silencer has a first molded surface and a second molded surface which are opposite to each other in a thickness direction. The silencer at least includes a first fiber layer on which the first molded surface is formed and a second fiber layer integrated with an opposite surface to the first molded surface, the opposite surface being on the first fiber layer. Fibers of the second fiber layer exist partly on the opposite surface on the first fiber layer.
    Type: Application
    Filed: August 23, 2017
    Publication date: December 28, 2017
    Inventors: Shuzo IWATA, Arata TAJIMA, Takahiko TANIGUCHI, Junpei SHIMOMURA, Kazuya KUSAMA
  • HETEROCYCLIC COMPOUND
    Publication number: 20170233339
    Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 17, 2017
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshihiro BANNO, Masahiro KAMAURA, Takahiko TANIGUCHI, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
  • NITROGENATED HETEROCYCLIC COMPOUND
    Publication number: 20170129887
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 13, 2016
    Publication date: May 11, 2017
    Inventors: Satoshi MIKAMI, Shinji NAKAMURA, Tomoko ASHIZAWA, Shigekazu SASAKI, Takahiko TANIGUCHI, Izumi NOMURA, Masanori KAWASAKI
  • PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20170114044
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0) wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    Type: Application
    Filed: December 13, 2016
    Publication date: April 27, 2017
    Inventors: Takahiko TANIGUCHI, Akira KAWADA, Mitsuyo KONDO, John F. QUINN, Jun KUNITOMO, Masato YOSHIKAWA, Makoto FUSHIMI
  • Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals
    Patent number: 9579407
    Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: February 28, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takahiko Taniguchi, Shotaro Miura, Tomoaki Hasui, Christer Halldin, Vladimir Stepanov, Akihiro Takano
  • Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders
    Patent number: 9550756
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: January 24, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takahiko Taniguchi, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
  • SILENCER FOR AUTOMOBILE
    Publication number: 20170008462
    Abstract: The present invention discloses a silencer for automobile. The silencer is formed by press molding. The silencer has a first molding surface and a second molding surface which are opposite to each other in a thickness direction. The silencer includes a buffer material in which fibers are oriented in the thickness direction and a fiber assembly in which fibers are oriented in a different direction from the direction of the fibers of the buffer material. The buffer material in which fibers are oriented in the thickness direction is inserted into the fiber assembly in which fibers are oriented in the different direction so that a lamination portion is formed by partly laminating the buffer material on the fiber assembly.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 12, 2017
    Inventors: Takahiko TANIGUCHI, Wataru HASHIMOTO, Itaru ASHIMINE
  • Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
    Patent number: 9527841
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: December 27, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Kawasaki Masanori, Izumi Nomura, Tomoko Ashizawa, Takahiko Taniguchi
  • Nitrogenated heterocyclic compound
    Patent number: 9469637
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: October 18, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Shigekazu Sasaki, Takahiko Taniguchi, Izumi Nomura, Masanori Kawasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20160264536
    Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 15, 2016
    Inventors: Masaki SETO, Yoshihiro BANNO, Toshihiro IMAEDA, Yuichi KAJITA, Tomoko ASHIZAWA, Masanori KAWASAKI, Shinji NAKAMURA, Satoshi MIKAMI, Izumi NOMURA, Takahiko TANIGUCHI, Shogo MARUI
  • HETEROCYCLIC COMPOUND
    Publication number: 20160159808
    Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 9, 2016
    Inventors: Masanori Kawasaki, Satoshi Mikami, Shinji Nakamura, Nobuyuki Negoro, Shuhei Ikeda, Izumi Nomura, Tomoko Ashizawa, Toshihiro Imaeda, Masaki Seto, Shigekazu Sasaki, Shogo Marui, Takahiko Taniguchi
  • Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
    Patent number: 9226921
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 5, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata, John F. Quinn, Joseph Raker, Fatoumata Camara, Yi Wang
  • Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
    Patent number: 9150588
    Abstract: A compound having PDE inhibitory represented by formula (1), W1-W2 (1), wherein (i) W1 is and W2 is (ii) W1 is and W2 is or (iii) W1 is and W2 is or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: October 6, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo
  • Heterocyclic compound
    Patent number: 9090586
    Abstract: The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 28, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato Yoshikawa, Shinkichi Suzuki, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo, Haruhi Kamisaki, Takahiko Taniguchi
  • HETEROCYCLIC COMPOUND
    Publication number: 20150158863
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 11, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Kawasaki Masanori, Izumi Nomura, Tomoko Ashizawa, Takahiko Taniguchi
  • Fused heterocyclic compounds
    Patent number: 9029536
    Abstract: The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: May 12, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Joseph Raker, Takahiko Taniguchi, Masato Yoshikawa, Tomoaki Hasui, Jun Kunitomo
  • Condensed heterocyclic compound
    Patent number: 9029388
    Abstract: The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: May 12, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Jun Kunitomo, Masato Yoshikawa, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Haruhi Kamisaki, Shinkichi Suzuki, Kasei Miura